US biopharma company Longevity Biomedical to go public via Denali Capital
Longevity Biomedical, an American biopharmaceutical company, will go public through a merger with Denali Capital Acquisition Corp., a special purpose acquisition company. The combined entity with a pro forma equity valuation of approximately $236.2 million, will operate as Longevity Biomedical, Inc. and is expected to list on Nasdaq. Longevity Biomedical develops and acquires new technologies […]